Cytokines and mycoses

Medical Mycology, Supplement

Volumn 36, Issue 1, 1998, Pages 174-182

  Stevens, D A ^a,f   Walsh, T J ^b   Bistoni, F ^c   Cenci, E ^c   Clemons, K V ^a   Del Sero, G ^c   D'Ostiani, C F E ^c   Kullberg, B J ^d   Mencacci, A ^c   Roilides, E ^e   Romani, L ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Cell mediated immunity; Cytokines; Immunology; Immunotherapy; Mycoses

Indexed keywords

CYTOKINE;

CELLULAR IMMUNITY; CONFERENCE PAPER; IMMUNE DEFICIENCY; IMMUNOTHERAPY; MYCOSIS; RECOMBINANT DNA TECHNOLOGY;

ANIMALS; CYTOKINES; FUNGI; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MYCOSES;

EID: 2042423023     PISSN: 09668454     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (81)

1. H2-like switch in candidiasis: new perspectives for therapy. Trends Micrbiol 1995; 3: 237-40.
2. Odds FC. Candida and Candidosis. 2nd edn. Baillère Tindall, London 1988.
3. Nelson RD, Shibata N, Podzorski RP, Herron MJ. Candida mannan: chemistry, suppression of cell-mediated immunity and possible mechanisms of action Clin Microbiol Rev 1991; 4: 1-19
4. Romani L, Howard DH. Mechanisms of resistance to fungal infections. Cur Opin Immunol 1995; 7: 517-23.
5. Romani L, Puccetti P, Bistoni F. Biological role of helper T-cell subsets in candidiasis. Chem Immunol 1995; 63: 113-37.
6. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
7. Lehrer RI. Measurement of candidacidal activity of specific leukocyte types in mixed cell populations. I. Normal, myeloperoxidase deficient and chronic granulomatous disease neutrophils. Infect Immun 1970; 2: 42-7.
8. Schaffner A, Davis CE, Schaffner T, Marker M, Douglas H, Braude AI. In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J Clin Invest 1986; 78: 511-24.
9. Diamond RD, Clark RA, Haudenschild CC. Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro. J Clin Invest 1980; 66: 908-17.
10. Cassatella MA, Meda L, Gasperini S, D'Andrea A, Ma S, Trinchieri G. Interleukin-12 production by human polymorphonuclear leukocytes. Eur J Immunol 1995; 25: 1-5.
11. Lloyd AR, Oppenheim JJ Poly's lament. The neglected role of polymorphonuclear neutrophil in different limbs of the immune response. Immunol Today 1992; 13: 169-72.
12. Romani L, Mencacci A, Cenci E, Del Sero G, Bistoni F, Puccetti P. An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. J Immunol 1997; 158: 2356-62.
13. Romani L, Mencacci A, Cenci E, Spaccapelo R, Del Sero G, Nicoletti I, Trinchieri G, Bistoni F, Puccetti P. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol 1997; 158: 5349-56.
14. Ashman RB, Padadimitriou JM. Production and function of cytokines in natural and acquired immunity to Candida albicans infections. Microbiol Rev 1995; 59: 646-72.
15. Djeu JY, Blanchard DK, Halkias D, Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-γ and tumor necrosis factor. J Immunol 1986; 137: 2980-4.
16. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects of granulocyte colony-stimulating factor and interferon-γ on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leuk Biol 1995; 57: 651-6.
17. Kullberg BJ, Van't Wout JW, Hoogstraten C, Van Furth R. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993; 168: 436-43.
18. Kullberg BJ, Van't Wout JW, Van Furth R. Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990; 58: 3319-24.
19. Van't Wout JW, Van der Meer JWM, Barza M, Dinarello CA. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur J Immunol 1988, 18: 1143-6.
20. Kullberg BJ, Van't Wout JW, Poell RJM, Van Furth R. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in mice. Antimicrob Agents Chemother 1992; 36: 1225-9.
21. Vogels MTE, Van der Meer JWM. Use of immune modulators in nonspecific therapy of bacterial infections. Antimicrob Agents Chemother 1992; 36: 1-5.
22. Romani L, Mencacci A, Cenci E, Spaccapelo R, Toniatti C, Puccetti P, Bistoni F, Poli V. Impaired neutrophil response and CD4+T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med 1996; 183: 1345-55.
23. Netea MG, Blok WL, Kullberg BJ, Bemelmans M, Vogels MTE, Buurman WA, Van der Meer JWM. Pharmacological inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995; 171: 393-9.
24. Steinshamn S, Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun 1992; 60: 4003-8.
25. Yamamoto Y, Klein TW, Friedman H, Kimura S, Yamaguchi H. Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol Med Microbiol 1993; 7: 15-22.
26. Vitt CR, Fidler JM, Ando D, Zimmerman RJ, Aukerman SL. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat. J Infect Dis 1994; 169: 369-74.
27. Hume DA, Denkins Y. The deleterious effect of macrophage colony-stimulating factor (CSF-1) on the pathology of experimental candidiasis in mice. Lymph Cyto Res 1992; 11: 95-8.
28. Graybill JR, Bocanegra R, Luther M Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol Infectious Dis 1995; 14: 700-3.
29. Netea MG, Kullberg BJ, Meis JFGM, Curfs JHAJ, Van der Meer JWM. Granulocyte-colony-stimulating factor protects non-neutropenic mice against disseminated candidiasis. Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, D.C 1996.
30. Graybill JR. Histoplasmosis and AIDS. J Infect Dis 1988; 158: 623-6.
31. Johnson PC, Sarosi GA. Progressive disseminated histoplasmosis in patients with AIDS. HIV Adv Res Ther 1994; 4: 15-21.
32. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infectious Dis 1993; 17: 837-42.
33. Stevens DA. Fungal infections in AIDS patients. Br J Clin Prac 1990; 44 (Suppl. 71): 11-22.
34. Aguirre K, Havell EA, Gibson GW, Johnson LL. Role of tumor necrosis factor and gamma Interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun 1995; 63: 1725-31.
35. Buchanan KL, Murphy JW. Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun 1993; 61: 2854-65.
36. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994; 38: 460-4.
37. Deepe GS. The immune response to Histoplasma capsulatum: unearthing its secrets. J Lab Clin Med 1994; 123: 201-5.
38. Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170: 1331-4.
39. Salkowski CA, Balish E. A monoclonal antibody to gamma-interferon blocks augmentation of natural killer cell activity induced during systemic cryptococcosis. Infect Immun 1991; 59: 486-93.
40. Wu-Hsieh BA, Howard DH Inhibition of the intracellular growth of Histoplasma capsulatum by recombinant murine gamma interferon. Infect Immun 1987; 55: 1014-6.
41. Zhou P, Sieve MC, Bennett J, Kwon-Chung KJ, Tewari RP, Gazzinelli RT, Scher A, Seder RA. IL-12 prevents mortality of mice infected with Histoplasma capsulatum through the induction of IFN-γ. J Immunol 1995; 155: 785-95.
42. Lutz JE, Clemons KV, Darbonne WC, Curnutte JT, Stevens DA. Role of interferon-gamma (IFN-γ) in defense against systemic cryptococcosis: in vivo studies with anti-IFN-γ antibody. Clin Infect Dis 1996; 23: 899 (abstract).
43. Lutz JE, Clemons KV, Stevens DA. Synergy between interferon-gamma and antifungal chemotherapy in systemic cryptococcosis. Clin Infect Dis 1996; 23: 899 (abstract).
44. Clemons KV, Lutz JE, Stevens DA Synergistic efficacy of interferon-gamma and amphotericin B against histoplasmosis. Abstracts, Annual Meeting of the American Society for Microbiology 1997; No. F-75.
45. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 cases. Rev Infect Dis 1990; 12: 1147-201.
46. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol 1991; 9: 77-84.
47. Walsh TJ, Dixon DM. Nosocomial aspergillosis: Environmental microbiology, hospital epidemiology, diagnosis, and treatment. Eur J Epidemiol 1989; 5: 131-12.
48. Roilides E, Pizzo PA. Perspectives on the use of cytokines in the management of infectious complications of cancer. Clin Infect Dis 1993; 17(Suppl. 2): S385-S391.
49. Wingard JR, Elfenbein GJ. Host immunologic augmentation for the control of infection. Infect Dis Clin North Am 1996; 10: 345-64.
50. Berenguer J, Allende MC, Lee JW, Garrett K, Lyman C, Ali NM, Bacher J, Pizzo PA, Walsh TJ. Pathogenesis of invasive pulmonary aspergillosis during persistent granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am Rev Respir Dis 1995; 152: 1079-86.
51. Walsh TJ, Bacher J, Pizzo PA. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab Anim Med 1988; 38: 467-71.
52. Walsh T, Gonzalez C, Lyman C, Lee S, Del Guercio C, Gehrt A, Sein T, Roilides E, Schaufele R, Francesconi A, Pizzo P. Human recombinant macrophage colony stimulating factor (MCSF) augments pulmonary host defense against Aspergillus fumigatus. Abstracts, Annual Meeting of the American Society for Microbiology, p. 593, 1994.
53. Walsh TJ, Garrett K, Feuerstein E, Girton M, Allende M, Francesconi A, Schaufele R, Pizzo PA. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography: a novel non-invasive method for measuring responses of organism-mediated tissue injury. Antimicrob Agents Chemother 1995; 39: 1065-9.
54. Roilides E, Sein T, Holmes A, Chanock S, Blake C, Pizzo PA, Walsh TJ. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis 1995; 172: 1028-34.
55. Bodey GP. Fungal infections complicating acute leukemia. J Chron Dis 1966; 19: 667-87.
56. Diamond RD, Krzesicki R, Epstein B, Jao W. Damage to hyphal forms of fungi by human leukocytes in vitro: a possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol 1978; 91: 313-28.
57. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345-51.
58. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus: observations on these two lines of defense in vitro and in vitro with human and mouse phagocytes. J Clin Invest 1982; 69: 617-31.
59. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by neutrophils to Aspergillus fumigatus hyphae by granulocyte colony stimulating factor and interferon-gamma. Infect Immun 1993; 61: 1185-93.
60. Rex JH, Bhalla SC, Cohen DM, Hester JP, Vartivarian SE, Anaissie EJ. Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and storage by interferon-gamma and granulocyte-colony-stimulating factor. Transfusion 1995; 35: 605-11.
61. Roilides E, Holmes A, Blake C, Venzon D, Pizzo PA, Walsh TJ. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-γ. J Infect Dis 1994; 170: 894-9.
62. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis 1983; 148: 230-8.
63. Walsh TJ, Mendelsohn G. Invasive aspergillosis complicating Cushing's syndrome. Arch Intern Med 1981; 141: 1227-8.
64. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61: 4870-7.
65. Roilides E, Dimitriadou A, Kadiltsoglou I, Sein T, Karpouzas J, Pizzo PA, Walsh TJ. Interleukin-10 exerts both suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Immunol 1997; 158: 322-9.
66. Vazquez N, Lyman CA, Friedman D, Walsh TJ, Chanock SJ. Interleukin 15 augments human monocyte activation. Blood 1995; 68 (Suppl. 1): 32a (abstract).
67. Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 654-62.
68. Minamoto GY, Barlan TF, Vander Els NJ. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1992; 14: 66-74.
69. Shetty D, Giri N, Gonzalez CE, Pizzo PA, Walsh TJ. Invasive aspergillosis in HIV-infected children. Ped Infect Dis J 1997; 16: 216-21.
70. Schaffner A. Pulmonary aspergillosis in AIDS (Letter). N Engl J Med 1991; 325: 355.
71. Stevens DA, Denning DW. Pulmonary aspergillosis in AIDS (Letter). N Engl J Med 1991; 325, 356-7.
72. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Impairment of neutrophil fungicidal activity against Aspergillus fumigatus in HIV-infected children. J Infect Dis 1993; 167: 905-11.
73. Chinn RYW, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: Relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982; 38: 1123-9.
74. Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun 1982; 38: 487-95.
75. Diamond RD, Haudenschild CC, Erickson NF. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun 1982; 38: 292-7
76. Levitz S, Selsted ME, Ganz T, Lehrer RI, Diamond RD. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis 1986; 154: 483-9.
77. Waldorf AR, Diamond R. Neutrophil chemotactic responses induced by fresh and swollen Rhizopus oryzae spores and Aspergillus fumigatus conidia. Infect Immun 1985; 48: 458-63.
78. Waldorf AR, Levitz S, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984; 150: 752-60.
79. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984; 74: 150-60.
80. Roilides E, Pizzo PA. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 1992; 15: 508-24.
81. Graybill JR. The future of antifungal therapy. Clin Infect Dis 1996; 22 (Suppl. 2): S166-78.